Artificial intelligence for the evaluation of movements in DMD

Clinical trials using force or movement measurements are highly dependent on patient motivation. To overcome this bias, British researchers developed a biomedical device with whole-body motion sensors to measure kinetic activity in real life:

  • 21 patients with Duchenne muscular dystrophy (DMD) participated in the study,
  • 18 were still ambulant versus three non-ambulant,
  • the data obtained were compared to those of a population of 17 healthy volunteers,
  • The experiment lasted one year.

The authors developed a behavioral biomarker called “KineDMDethomic” and defined specific trajectories for each patient with DMD.


Wearable full-body motion tracking of activities of daily living predicts disease trajectory in Duchenne muscular dystrophy. Ricotti V, Kadirvelu B, Selby V et al. Nat Med. 2023 Jan;29(1):95-103.